GSK Trust in ScienceA novel public-private-partnership model for discovery and development
September 2018
Isro Gloger, PhDDirector, Trust in ScienceGlobal Health R&D
GSK trust in science
GSK Brazil at a Glance
• Presence in Brazil for 106 years, since 1908
• Two manufacturing plants, one in RJ and one in SP
• Employs ~ 2000 people & exports to 11 Latin America
countries
• Pioneered technology and knowledge transfer to the
Brazilian Government and scientists for more than 25
years
• Over 40 clinical studies ongoing
3
Trust in Science
Promote GSK as a partner of choice in Latin
America and Africa and contribute to GSK’s
research through scientific interactions with top
local research organisations
GSK trust in science
Scientific
ExcellenceTrust
Talent
Development
Public-private partnership activity in Brazil pioneered by GSK
4
GSK Trust in Science Activities and achievements in Brazil
GSK
Government
Funding
Agencies
Co-funding
Research Projects
and Talent Development
Relevance to
patients
Quality of
scienceCollaborative
working model
Build long-term
trust
Initiative started in 2011
5
Trust in Science Activities between 2012-2018
“Science without
Borders” .
13 fellows trained
at GSK
GSK UK
Residential training
for Brazilian
Chemistry Graduates
Jan 2013, Jan 2014
9 Research projects
approved in 2011
GSK FUNDING
3 year agreement
signed with(2011-2014)
4 projects co-funded
10 year agreement
signed with(2015-2025)
Center of Excellence for Drug
Discovery co-funded
10 year agreement
signed with(2015-2025)
Center of Excellence for
Sustainable Chemistry
6
Key universities supported in Brazil
University of Bahia
University of San Carlos (UFSCar)
University of Minas Gerais
University of Rio de Janeiro
University of Campinas (UNICAMP)
University of São Paulo (USP)
São Paulo State University (UNESP)
Santa Catarina Federal University (UFSC)
Butantan Institute has one
of the world biggest
collections of snake venoms
A.M. Chudzinski
Denise Tambourgi
Disease models
Phenotypic screening of
in vitro 3D models of
inflammation
Deconvolution of positive hits
to unravel new pathways/targets
Centre of Excellence in BrazilButantan Institute, Sao Paulo
In vitro systems
Animal models
David Tough
Isro Gloger
Kevin Madauss
Chris Larminie
Gauthier Koscielny
Jonathan Larkin
Gerard Drewes
Richard Carroll
GSK trust in science
8
GSK investment in Brazil
GSK makes $1M average
investment per year
Total investment 2011-2017
$6M US Dollars
Committed investment 2018-2025
$10M US Dollars
Matching funds agreement with
FAPESP
Total investment GSK
$18M US Dollars+ Matching funds from FAPESP
New Partnership in the state of Sao Paulo
Support of innovative scientific research
projects of start-ups in the health area under the
FAPESP PIPE Programme
FAPESP’s Program of Innovative Research in Small Business - PIPE, provides support for small and medium enterprises in the State of São Paulo to develop research
New Partnership in the state of Sao Paulo
Call for proposals focused on
Immuno-inflammation Respiratory diseases,
Immuno-oncology HIV
New Partnership in the state of Sao Paulo
• Up to 10 proposals selected in the first round
R200.000 from FAPESP for each proposal for 9 months
• Up to 3 of these proposals selected for further funding
R1.000.000 from FAPESP for 2 years
New Partnership in the state of Sao Paulo
-Financial support
-Institutional support -Scientific in kind support
-Mentoring
-Technical guidance
-Regular contact
In kind corporate and
organisational
support.
Access to network
and investors
Process for application and funding
• Call for proposals published at FAPESP’s website (September 2018). Open until 09/2020.
• Small or medium companies (up to 5 individuals) in State of Sao Pablo eligible to apply
• Therapeutic areas: Immuno-Inflammation, Immuno-Oncology, Respiratory, HIV.
Preferable projects in early stage of innovation including transformational ideas.
• Eligible proposals will be reviewed jointly by FAPESP-GSK-Biominas + external peer
review
• Projects selected will receive financing from FAPESP and support letters from GSK
and Biominas
• Selected projects (up to 3) to receive initial funding of 9 months.
• 3 of those projects to receive further 2 year financial support.
• IP generated belongs to investigator. GSK will have first option to negotiate on the IP
generated.
14
Trust in Science: a great private-public partnership!
Researchers
Government
Funding Agencies
Isro Gloger
Local Operating Companies
Discovery Units
Legal, Communications,
Business Development
Academic Liaisons
GSK trust in science
